Relationship between JAK2-V617F mutation and hematologic parameters in Philadelphia-negative chronic myeloproliferative neoplasms
| Autor: | Merve Zeytinli Aksit, Can Ozlu, Giray Bozkaya, Murat Aksit, Nuriye Uzuncan, Sibel Bilgili |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
Philadelphia negative business.industry Biochemistry (medical) Clinical Biochemistry Biochemistry 03 medical and health sciences 030104 developmental biology 0302 clinical medicine hemic and lymphatic diseases 030220 oncology & carcinogenesis Mutation (genetic algorithm) Cancer research Medicine business Molecular Biology JAK2 V617F |
| Zdroj: | Turkish Journal of Biochemistry. 45:899-905 |
| ISSN: | 1303-829X 0250-4685 |
| DOI: | 10.1515/tjb-2020-0267 |
| Popis: | Objectives We aimed to investigate the prevalence of JAK2-V617F mutation and its association with hematologic parameters in polycythemia vera(PV), essential thrombocytosis(ET) and primary myelofibrosis(PMF) patients who have been tested for the mutation. Methods We retrospectively reviewed the records of 168 patients (82 males and 86 females) who were tested for JAK2-V617F mutation upon request of Hematology Clinic. JAK2-V617F mutation status, white blood cell (WBC) counts, platelet (PLT) counts, hemoglobin (Hb), hematocrit (Hct) levels and demographics of the patients were recorded. Results JAK2-V617F mutation was detected in 55.9% of the 168 patients. The mutation was observed in 58.2% of PV cases, in 54.4% of ET and in 54.5% of PMF cases. All patients were divided into two groups: mutation positive and negative. Age, WBC and PLT levels were significantly higher in mutation positive group (p Conclusion JAK2-V617F mutation is a very important parameter in diagnostic and prognostic evaluation. Thus, every patient suspected of having a myeloproliferative neoplasm should be screened for JAK2-V617F mutation. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|